Hutchmed Share News (HCM)

Hutchmed China's colorectal cancer study to be published

(Sharecast News) - Hutchmed China, alongside its partner Takeda, announced the publication of the phase three 'FRESCO-2' study results evaluating the use of fruquintinib in patients with previously-treated metastatic colorectal cancer (CRC) on Friday, in the Lancet medical journal.

IN BRIEF: Hutchmed and Takeda get Europe marketing backing for drug

Hutchmed (China) Ltd - Hong Kong-based cancer and immunological diseases treatment developer - Says marketing authorisation application for fruquintinib, made alongside Tokyo-based Takeda Pharmaceutical Co Ltd, has been validated and caccepted by the European Medicines Agency. Fruquintinib is an inhibitor of vascular endothelial growth factor receptors used to treat cancers.

US FDA gives priority to Hutchmed's colorectal cancer treatment

(Sharecast News) - Hutchmed China, in collaboration with Takeda, announced on Friday that the US Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) of fruquintinib.

Hutchmed China celebrates FDA review, teases new data at ASCO meeting

(Alliance News) - Hutchmed China Ltd on Friday celebrated a priority review granted by the US FDA for its cancer drug fruquintinib, and promised to present new data for this and two other therapies at the American Society of Clinical Oncology next month.

UK shareholder meetings calendar - next 7 days

Hutchmed's gastric cancer treatment accepted for review in China

(Sharecast News) - Hutchmed China announced on Tuesday that its new drug application (NDA) for fruquintinib, in combination with paclitaxel has been accepted for review by the National Medical Products Administration (NMPA) in China.

Hutchmed gets Chinese approval for fruquintinib new drug application

(Alliance News) - Hutchmed (China) Ltd on Tuesday said the China National Medical Products Administration accepted its new drug application for fruquintinib in combination with paclitaxel.

Hutchmed to start registration phase enrolments for two treatments

(Alliance News) - Hutchmed China Ltd on Tuesday said it will start registration phase enrolments for two of its prospective treatments under study, HMPL-453 and savolitinib.

Hutchmed completes rolling FDA submission for colorectal cancer drug

(Sharecast News) - Pharmaceuticals developer Hutchmed China announced the completion of its rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for its oral inhibitor 'fruquintinib'.

Hutchmed submits new drug application to US FDA for cancer treatment

(Alliance News) - Hutchmed (China) Ltd on Friday said it has completed the rolling submission of a new drug application for its fruquintinib cancer drug to the US Food & Drug Administration.

Hutchmed China inks global licensing deal with Takeda on fruquintinib

(Alliance News) - Hutchmed China Ltd on Tuesday said it closed a license agreement with a subsidiary of Tokyo-based drug maker Takeda Pharmaceutical Co Ltd for fruquintinib.

DIRECTOR DEALINGS: Hutchmed CFO banks GBP4 million; Haleon chair buys

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Tuesday and Wednesday and not separately reported by Alliance News:

Hutchmed expects revenue climb from oncology, immunology division

(Alliance News) - Hutchmed (China) Ltd expects a sharp rise in revenue from its oncology and immunology-focused arm, as the biopharmaceutical firm looks forward to a productive 2023.

Hutchmed enrols last patient in lymphoma treatment trial

(Sharecast News) - Hutchmed China announced the completion of patient enrollment in a phase two registration trial of 'amdizalisib' on Monday, for the treatment of relapsed or refractory follicular lymphoma (FL), which is a subtype of non-Hodgkin's lymphoma.

Hutchmed completes patient enrolment for trial testing cancer therapy

(Alliance News) - Hutchmed (China) Ltd on Monday said that it has completed patient enrolment for the Phase Two registration trial of amdizalisib, its once-a-day oral monotherapy in patients with relapsed or refractory follicular lymphoma.